FDA Accepts United Therapeutics' Application for Expanded Use of Nebulized Tyvaso
United Therapeutics (UTHR) has announced that the U.S. Food and Drug Administration (FDA) accepted its marketing application to expand the label for nebulized Tyvaso, a treatment primarily used in pulmonary arterial hypertension, to include idiopathic pulmonary fibrosis. The FDA's acceptance of this application marks an important step toward potentially broadening access to the drug for patients with IPF. The agency is expected to complete its review process soon, though no specific timeline was provided by United Therapeutics at this time.
Tickers: $UTHR